A detailed history of Nelson, Van Denburg & Campbell Wealth Management Group, LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Nelson, Van Denburg & Campbell Wealth Management Group, LLC holds 21 shares of SRPT stock, worth $2,388. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21
Holding current value
$2,388
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025

BUY
$104.54 - $137.94 $2,195 - $2,896
21 New
21 $2,000
Q1 2024

Apr 30, 2024

BUY
$93.7 - $141.53 $17,147 - $25,899
183 New
183 $23,000
Q3 2023

Oct 17, 2023

BUY
$102.5 - $123.59 $127,715 - $153,993
1,246 Added 60.81%
3,295 $399,000
Q2 2023

Jul 19, 2023

SELL
$106.4 - $157.19 $136,085 - $201,046
-1,279 Reduced 38.43%
2,049 $234,000
Q4 2022

Feb 14, 2023

BUY
$100.86 - $132.13 $59,910 - $78,485
594 Added 21.73%
3,328 $431,000
Q3 2022

Oct 26, 2022

BUY
$75.71 - $119.24 $206,991 - $326,002
2,734 New
2,734 $302,000
Q1 2021

May 11, 2021

SELL
$72.25 - $168.95 $260,894 - $610,078
-3,611 Closed
0 $0
Q4 2020

Feb 09, 2021

SELL
$125.56 - $178.74 $94,044 - $133,876
-749 Reduced 17.18%
3,611 $615,000
Q3 2020

Oct 20, 2020

BUY
$127.12 - $172.34 $101,696 - $137,872
800 Added 22.47%
4,360 $612,000
Q1 2020

Apr 01, 2020

BUY
$82.38 - $131.64 $23,066 - $36,859
280 Added 8.54%
3,560 $348,000
Q3 2019

Oct 09, 2019

BUY
$72.81 - $156.91 $35,676 - $76,885
490 Added 17.56%
3,280 $247,000
Q1 2019

May 08, 2019

BUY
$106.67 - $151.68 $125,870 - $178,982
1,180 Added 73.29%
2,790 $332,000
Q4 2018

Feb 13, 2019

BUY
$97.32 - $148.76 $98,293 - $150,247
1,010 Added 168.33%
1,610 $175,000
Q3 2018

Nov 14, 2018

BUY
$115.31 - $161.51 $69,186 - $96,906
600 New
600 $97,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.96B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Nelson, Van Denburg & Campbell Wealth Management Group, LLC Portfolio

Follow Nelson, Van Denburg & Campbell Wealth Management Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nelson, Van Denburg & Campbell Wealth Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nelson, Van Denburg & Campbell Wealth Management Group, LLC with notifications on news.